The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Castration resistance and high-risk disease among nonmetastatic (M0) prostate cancer (PC) patients on androgen deprivation therapy (ADT).
Melissa Pirolli
Research Funding - Amgen
Rohini Khorana Hernandez
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Karynsa Cetin
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Jane Quigley
No relevant relationships to disclose
Yanina Grant-Huerta
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Scott Stryker
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Paul Smith
No relevant relationships to disclose
John Adams
Consultant or Advisory Role - Amgen
Alexander Liede
Employment or Leadership Position - Amgen
Stock Ownership - Amgen